The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system.
Elenkov, I J, Wilder, R L, Chrousos, G P et al. · Pharmacological reviews · 2000
Quick Summary
Your brain and immune system communicate constantly to keep your body healthy, and your nervous system plays a key role in this conversation. This review explains how nerve signals release chemicals called norepinephrine and epinephrine that can either calm down or activate your immune system depending on where in your body they act. Understanding this communication system may help explain why chronic conditions like fatigue syndromes involve both nervous system and immune system problems.
Why It Matters
ME/CFS is characterized by dysregulated immune responses and autonomic nervous system dysfunction; this review provides a mechanistic framework for understanding how impaired sympathetic-immune communication could simultaneously cause excessive inflammatory responses in some contexts while failing to mount adequate defenses in others. The proposed pharmacological interventions (selective adrenoreceptor modulators, phosphodiesterase inhibitors) specifically mentioned for chronic fatigue syndrome suggest direct clinical relevance to ME/CFS pathophysiology.
Observed Findings
Sympathetic nerve terminals extensively innervate primary and secondary lymphoid organs (thymus, bone marrow, mucosal tissues) and release norepinephrine onto immune cells
Norepinephrine and epinephrine suppress type 1/proinflammatory cytokine production (IL-12, TNF-α, IFN-γ) while enhancing type 2/anti-inflammatory cytokines (IL-10, TGF-β) through β2-adrenoreceptor-cAMP-PKA signaling
Catecholamines modulate lymphocyte trafficking, proliferation, and functional activity in dose- and location-dependent ways
Systemic catecholamine elevation causes Th1 suppression and shift toward Th2 humoral immunity dominance, while local sympathetic activation may enhance regional inflammatory responses
Inferred Conclusions
The sympathetic nervous system functions as a key integrator between brain and immune system, capable of both suppressing systemic Th1 responses and localizing inflammatory responses depending on context
Dysregulation of SNS-immune signaling could contribute to pathological immune responses in autoimmune disease, chronic pain, chronic fatigue syndromes, and other conditions
Pharmacological targeting of adrenoreceptor signaling may offer therapeutic benefit in conditions involving SNS-immune dysfunction
Remaining Questions
What specific defects in sympathetic innervation or adrenoreceptor signaling occur in ME/CFS patients, and do these vary between patient subgroups?
What This Study Does Not Prove
This review does not provide direct clinical evidence that sympathetic-immune dysregulation causes ME/CFS, nor does it establish whether observed immune abnormalities in ME/CFS patients result from primary SNS dysfunction or secondary immune activation. The mechanistic concepts are largely derived from experimental models and acute infection/injury states rather than chronic disease models, limiting direct extrapolation to ME/CFS pathogenesis.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
How does chronic/sustained activation of immune responses affect the ability of the sympathetic nervous system to mount appropriate modulatory responses?
Which adrenoreceptor-targeting drugs (α2 or β2 agonists/antagonists, PDE4 inhibitors) would be most effective and tolerable in ME/CFS, and in which patient phenotypes?